Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-authorisation Observational Registry to Assess the Clinical Impact of Initiating Anti-tumour Rescue Therapy in Patients With Multiple Myeloma (MM) in Asymptomatic Biological Relapse Compared to Initiating Treatment at the Time of Symptomatic Relapse.

NCT02394210 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02394210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02394210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-authorisation Observational Registry to Assess the Clinical Impact of Initiating Anti-tumour Rescue Therapy in Patients With Multiple Myeloma (MM) in Asymptomatic Biological Relapse Compared to Initiating Treatment at the Time of Symptomatic Relapse.
Lead sponsor
Celgene
Phase
Observational
Overall status
Terminated
Start date
May 14, 2013
Completion date
May 18, 2021
Enrollment
415 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma